-
MDA Guest Ambassador: Ten Tips for High School Life with a Disability
Madison is from Baton Rouge, Louisiana, and lives with congenital muscular dystrophy. She is an […]
-
Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial of SGT-003
Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial […]
-
Hidden role of MYOD protein may lead to new MD therapies: Study
A protein called MYOD, which is known to control the growth of muscle stem cells […]
-
On the importance of human connection
There is power in connection. As humans, we all learn this truth at a young […]
-
Update to the U.S. Duchenne Community on the Ataluren (Translarna) for Nonsense Mutation Duchenne Muscular Dystrophy
The FDA is continuing its review of Ataluren (Translarna), the first potential therapy specifically for […]
-
In Case You Missed It…
Quest Media is an innovative adaptive lifestyle platform from MDA. With the power of this […]
-
Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs
Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of […]
-
Disabled artists’ challenges can propel creative solutions
As an artist with Duchenne muscular dystrophy (DMD), I’ve long recognized how creativity can foster […]
-
FSHD patients sought for first clinical trial testing EPI-321
Enrollment is now ongoing in a first-in-human trial testing EPI-321, an epigenetic therapy designed to […]
-
Behind the Drug: Nusinersen (Spinraza) for SMA
Spinal muscular atrophy (SMA) is a rare genetic disease that affects the peripheral nervous system […]
